PCN84 Preliminary Results of a Cost Effectiveness MODEL of Atezolizumab PLUS Bevacizumab in Unresectable Hepatocellular Carcinoma (HCC) in France

Abstract

Authors

C. Dubois de Gennes B. Mazaleyrat J. Sanchez Alvarez H. Cawston

Full Text Cite This Article
Back to Volume 23, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×